News


  • 27 March 2014

    Syndax Files Registration Statement for Proposed Initial Public Offering

    Syndax Files Registration Statement for Proposed Initial Public Offering

    Syndax Pharmaceuticals, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (“SEC”) relating to a proposed initial public offering of shares of its common stock. All shares of common stock to be sold in the offering will be offered by Syndax. The number of shares to be offered and the price range for the offering have not yet been determined.

  • 25 March 2014

    SIFI and NovaMedica sign agreement to market eight eye care products in Russia

    SIFI and NovaMedica sign agreement to market eight eye care products in Russia

    Leading Italian developer of innovative eye care solutions S.I.F.I. S.p.A. (SIFI) and Russian pharmaceutical company NovaMedica have entered into an exclusive commercial agreement  for NovaMedica to market eight products developed and licensed by SIFI for the treatment of a wide range of ophthalmic pathologies in Russia and the CIS.

  • 20 March 2014

    ECOG-ACRIN Opens Phase III Trial of SyndaxТs Entinostat in Advanced Breast Cancer

    ECOG-ACRIN Opens Phase III Trial of SyndaxТs Entinostat in Advanced Breast Cancer

    Entinostat is being investigated in patients with advanced hormone receptor-positive breast cancer by the ECOG-ACRIN Cancer Research Group in its latest trial, E2112.

  • 19 March 2014

    FDA Designates Regado's REG1 in PCI as a Fast Track Development Program

    FDA Designates Regado's REG1 in PCI as a Fast Track Development Program

    Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the development of actively controllable therapeutics, today announced that the United States Food and Drug Administration (FDA) has designated REG1 for anticoagulant therapy to be used in patients with coronary artery disease during percutaneous coronary interventions (PCI) as a Fast Track development program. The FDA's Fast Track process is designed to facilitate the development and expedite the review of drugs to treat serious conditions that fill an unmet medical need, with the overall goal of getting new drugs to patients earlier. 

  • 12 March 2014

    Regado Biosciences announces year-end 2013 financial results and corporate highlights

    Regado Biosciences announces year-end 2013 financial results and corporate highlights

    Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage, Phase 3 clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced its year-end 2013 corporate highlights and financial results. 

  • 13 February 2014

    Regado Biosciences, Inc., Announces FDA Acceptance of IND for REG2

    Regado Biosciences, Inc., Announces FDA Acceptance of IND for REG2

    Regado Biosciences, Inc., a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that the United States Food and Drug Administration (FDA) has accepted the company's investigational new drug (IND) application for REG2. Regado previously completed a single escalating-dose Phase 1 clinical trial of REG2 and plans to conduct additional clinical testing in sub-acute venous thrombosis indications in the future.

  • 13 February 2014

    Syndax Announces NCI And FDA Reach Agreement On A Special Protocol Assessment (SPA) For The Phase 3 Trial Of Entinostat In Patients With Advanced ER+ Breast Cancer

    Syndax Announces NCI And FDA Reach Agreement On A Special Protocol Assessment (SPA) For The Phase 3 Trial Of Entinostat In Patients With Advanced ER+ Breast Cancer

    Syndax Pharmaceuticals, Inc., today announced that the Division of Cancer Treatment and Diagnosis (DCTD) of the National Cancer Institute (NCI) has reached a special protocol assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) for the planned pivotal Phase 3 trial of entinostat in patients with advanced breast cancer. 

  • 12 February 2014

    Regado Biosciences, Inc., Broadens Patent Family Protecting Core Technology

    Regado Biosciences, Inc., Broadens Patent Family Protecting Core Technology

    Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the late-stage clinical development of its first-in-class, actively controllable antithrombotic drug system, REG1, today announced that the United States Patent and Trademark Office (USPTO) has issued an important patent that expands protection of Regado's core technology platform while broadening the range of aptamer-based therapies upon which Regado may base future products.

  • 12 February 2014

    Miramar Labs Secures $10 Million in Series D Funding

    Miramar Labs Secures $10 Million in Series D Funding

    Miramar Labs®, Inc., a leading medical device manufacturer and maker of the miraDry® System, announced today it has raised $10 million in Series D funding from Aisling Capital, Cross Creek Capital, Domain Associates, Morgenthaler Ventures, and RusnanoMedInvest. The new investment will be used to expand sales activities around the world, support commercialization efforts in Europe given the recent CE Mark approval and support R&D efforts on products for new indications.

  • 11 February 2014

    Lithera Announces Final Closing of $35.6 Million Series C Financing

    Lithera Announces Final Closing of $35.6 Million Series C Financing

    Lithera, Inc., a clinical stage pharmaceutical company focused on lifestyle and medical indications in aesthetic medicine and ophthalmology, today announced that it has completed the final closing of its Series C preferred stock equity financing, securing an additional $8.0 million in equity capital and bringing the total capital raised in this round to $35.6 million.